Trial · NCT00090259
Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
NCT00090259, Phase 3, Completed, Organon and Co; results first posted 2010-08-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948). Trials, record NCT00090259. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00090259
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)
- NCT number
- NCT00090259
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 3,834 participants, actual
- Lead sponsor
- Organon and Co
- Conditions
- Heart Failure
- Interventions
- Losartan 50 mg, Losartan 150 mg
- First posted
- 2004-08-27
- Last updated
- 2024-05-16
- Results first posted
- 2010-08-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure | Entire follow-up (median = 4.7 years) | |
| Secondary | Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization | Entire follow-up (median = 4.7 years) | Cardiovascular hospitalization is defined as any hospitalization that may be attributed to a cardiovascular cause, including heart failure. |
| Secondary | Number of Participants That Died (Any Cause) | Entire follow-up (median = 4.7 years) | |
| Secondary | Number of Participants That Were Hospitalized for Heart Failure | Entire follow-up (median = 4.7 years) | |
| Secondary | Number of Participants That Experienced Cardiovascular Hospitalization | Entire follow-up (median = 4.7 years) |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure | Entire follow-up (median = 4.7 years) | Intention-to-Treat | Participants | NUMBER |
| SECONDARY | Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization | Entire follow-up (median = 4.7 years) | Intention-to-Treat | Participants | NUMBER |
| SECONDARY | Number of Participants That Died (Any Cause) | Entire follow-up (median = 4.7 years) | Intention-to-Treat | Participants | NUMBER |
| SECONDARY | Number of Participants That Were Hospitalized for Heart Failure | Entire follow-up (median = 4.7 years) | Intention-to-Treat | Participants | NUMBER |
| SECONDARY | Number of Participants That Experienced Cardiovascular Hospitalization | Entire follow-up (median = 4.7 years) | Intention-to-Treat | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure | Losartan 50 mg | 889 | Participants | ||
| Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure | Losartan 150 mg | 828 | Participants | ||
| Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization | Losartan 50 mg | 1085 | Participants | ||
| Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization | Losartan 150 mg | 1037 | Participants | ||
| Number of Participants That Died (Any Cause) | Losartan 50 mg | 665 | Participants | ||
| Number of Participants That Died (Any Cause) | Losartan 150 mg | 635 | Participants | ||
| Number of Participants That Were Hospitalized for Heart Failure | Losartan 50 mg | 503 | Participants | ||
| Number of Participants That Were Hospitalized for Heart Failure | Losartan 150 mg | 450 | Participants | ||
| Number of Participants That Experienced Cardiovascular Hospitalization | Losartan 50 mg | 826 | Participants | ||
| Number of Participants That Experienced Cardiovascular Hospitalization | Losartan 150 mg | 762 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Losartan 50 mg | 1,913 | |
| Overall Study | STARTED | Losartan 150 mg | 1,921 | |
| Overall Study | COMPLETED | Losartan 50 mg | 1,851 | |
| Overall Study | COMPLETED | Losartan 150 mg | 1,873 | |
| Overall Study | NOT COMPLETED | Losartan 50 mg | 62 | |
| Overall Study | NOT COMPLETED | Losartan 150 mg | 48 |
Source ClinicalTrials.gov
Adverse events1,626
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Losartan 50 mg | 78 | 1,913 | |
| other | Anaemia | Blood and lymphatic system disorders | Losartan 150 mg | 108 | 1,921 | |
| other | Angina pectoris | Cardiac disorders | Losartan 50 mg | 100 | 1,913 | |
| other | Angina pectoris | Cardiac disorders | Losartan 150 mg | 100 | 1,921 | |
| other | Atrial fibrillation | Cardiac disorders | Losartan 50 mg | 123 | 1,913 | |
| other | Atrial fibrillation | Cardiac disorders | Losartan 150 mg | 130 | 1,921 | |
| other | Cardiac failure | Cardiac disorders | Losartan 50 mg | 231 | 1,913 | |
| other | Cardiac failure | Cardiac disorders | Losartan 150 mg | 200 | 1,921 | |
| other | Cardiac failure congestive | Cardiac disorders | Losartan 50 mg | 106 | 1,913 | |
| other | Cardiac failure congestive | Cardiac disorders | Losartan 150 mg | 92 | 1,921 |
1 to 10 of 1,626Source ClinicalTrials.gov
See all 1,626 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Losartan 50 mg | ||
| Total, all-cause mortality | Losartan 150 mg | ||
| Total, other adverse events | Losartan 50 mg | 1,358 | 1,913 |
| Total, other adverse events | Losartan 150 mg | 1,394 | 1,921 |
| Total, serious adverse events | Losartan 50 mg | 691 | 1,913 |
| Total, serious adverse events | Losartan 150 mg | 710 | 1,921 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons6
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Were Hospitalized for Heart Failure | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Died (Any Cause) | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Experienced One Components of the Composite Clinical Endpoint of All Cause Death or Cardiovascular Hospitalization | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: Number of Participants That Experienced Cardiovascular Hospitalization | Trial comparisons |
| Losartan 50 mg vs Losartan 150 mg: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00090259
GET https://conductscience.org/api/trials/v1/NCT00090259/events?page=2